Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 285 full-time employees. The company went IPO on 2018-09-14. The firm is also engaged in the commercialization of HuaTangNing products. The Company’s main product pipeline dorzagliatin or HMS5552 is a glucokinase activator or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The firm mainly conducts its businesses in the domestic market.
How did HUMDF's recent EPS compare to expectations?
The most recent EPS for Hua Medicine (Shanghai) Ltd. is $, expectations of $.
How did Hua Medicine (Shanghai) Ltd. HUMDF's revenue perform in the last quarter?
Hua Medicine (Shanghai) Ltd. revenue for the last quarter is $
What is the revenue estimate for Hua Medicine (Shanghai) Ltd.?
According to of Wall street analyst, the revenue estimate of Hua Medicine (Shanghai) Ltd. range from $ to $
What's the earning quality score for Hua Medicine (Shanghai) Ltd.?
Hua Medicine (Shanghai) Ltd. has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Hua Medicine (Shanghai) Ltd. report earnings?
Hua Medicine (Shanghai) Ltd. next earnings report is expected in 2025-11-25
What are Hua Medicine (Shanghai) Ltd.'s expected earnings?
Hua Medicine (Shanghai) Ltd. expected earnings is $, according to wall-street analysts.
Did Hua Medicine (Shanghai) Ltd. beat earnings expectations?
Hua Medicine (Shanghai) Ltd. recent earnings of $ expectations.